News & Updates
Long-term bone cancer survivor and ECI® patient featured on local news
Ruby the Greyhound was diagnosed with osteosarcoma in December 2016 and began the ELIAS cancer immunotherapy (ECI®). Today, Ruby is thriving and her story was recently featured on a Kansas City local news channel. Learn more about Ruby, one of five long-term survivors from the ELIAS preliminary study. Read the story
ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs
Ten sites now participating in trial of alternative treatment to chemotherapy for canine osteosarcoma Olathe, Kansas, Nov. 12, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces that 10 investigation sites across the U.S. are now participating in the pivotal trial of ELIAS cancer immunotherapy (ECI®). This marks an expansion of the study ELIAS initiated in May to pursue licensure of ECI treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. The geographical areas served by the clinical trial [...]
Clinical study results demonstrate long term survival in dogs with osteosarcoma treated with ELIAS cancer immunotherapy
Results of a clinical study of the ELIAS cancer immunotherapy (ECI®) protocol demonstrated that the administration of an autologous cancer cell vaccination, adoptive T cell transfer, and interleukin‐2 resulted in long‐term survival for dogs with osteosarcoma, a deadly form of bone cancer. The article, published in the Journal of Veterinary Internal Medicine by researchers from the University of Missouri, describes the 14-dog single-arm prospective study and discusses the results. The objective of the study was to evaluate the hypothesis that dogs could be treated safely with the ECI protocol, which includes administration of ex vivo activated T cells, and experience [...]